Friendswood – October 12, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.

The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.